CommercialCoverageMedium impact
08.00.10d, Luspatercept–aamt (Reblozyl®)
Independence Blue Cross·Hematology, Oncology·Pharmacy
Effective date
Jan 17, 2025
We identified it
Jun 19, 2026
Summary
Insurance policy for Luspatercept–aamt (Reblozyl®) has been updated with changes to coverage criteria, medical necessity requirements, and coding guidelines. This affects pharmacy billing for this specialty medication used primarily in hematology treatments.
Action Required
By January 17, 2025: Billing team must review updated medical necessity criteria for Luspatercept–aamt (Reblozyl®) claims. Update prior authorization workflows and documentation requirements in billing system. Verify coverage guidelines with providers who prescribe this medication to ensure compliance with new criteria.